CRIS Current Research Information System

BARBATO, SIMONA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.186
NA - Nord America 1.286
EU - Europa 863
SA - Sud America 151
AF - Africa 92
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.586
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.245
VN - Vietnam 946
SG - Singapore 414
CN - Cina 413
IT - Italia 371
HK - Hong Kong 116
BR - Brasile 107
DE - Germania 90
GB - Regno Unito 77
BD - Bangladesh 72
FR - Francia 64
KR - Corea 64
IN - India 52
SE - Svezia 51
NL - Olanda 45
FI - Finlandia 41
CI - Costa d'Avorio 30
IE - Irlanda 28
JP - Giappone 28
RU - Federazione Russa 26
CA - Canada 23
SC - Seychelles 19
ZA - Sudafrica 19
AR - Argentina 18
TG - Togo 12
AT - Austria 11
PL - Polonia 11
ES - Italia 9
IQ - Iraq 9
TW - Taiwan 9
MX - Messico 8
PH - Filippine 8
TH - Thailandia 8
JO - Giordania 7
AU - Australia 6
BG - Bulgaria 6
EC - Ecuador 6
ID - Indonesia 6
CO - Colombia 5
CZ - Repubblica Ceca 5
EE - Estonia 5
SA - Arabia Saudita 5
TR - Turchia 5
UZ - Uzbekistan 5
CL - Cile 4
HR - Croazia 4
MY - Malesia 4
UA - Ucraina 4
AE - Emirati Arabi Uniti 3
CH - Svizzera 3
IL - Israele 3
PK - Pakistan 3
PY - Paraguay 3
UY - Uruguay 3
VE - Venezuela 3
BS - Bahamas 2
CR - Costa Rica 2
EG - Egitto 2
GH - Ghana 2
GR - Grecia 2
GT - Guatemala 2
KE - Kenya 2
LT - Lituania 2
MA - Marocco 2
NP - Nepal 2
RO - Romania 2
RS - Serbia 2
TN - Tunisia 2
AL - Albania 1
BO - Bolivia 1
CW - ???statistics.table.value.countryCode.CW??? 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
KN - Saint Kitts e Nevis 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LK - Sri Lanka 1
MT - Malta 1
NG - Nigeria 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
PE - Perù 1
PR - Porto Rico 1
QA - Qatar 1
SK - Slovacchia (Repubblica Slovacca) 1
ZM - Zambia 1
Totale 4.586
Salva come PNG Salva come JPEG
Città #
Singapore 293
Ho Chi Minh City 284
Hanoi 232
Ashburn 162
Bologna 153
Hefei 120
Hong Kong 109
Chandler 102
San Jose 95
Dallas 91
Fairfield 64
Seoul 55
Santa Clara 47
Southend 45
Haiphong 41
New York 41
Lauterbourg 36
Beijing 32
Abidjan 30
Council Bluffs 30
Los Angeles 26
Dublin 24
São Paulo 24
Princeton 22
Tokyo 21
Boardman 20
Houston 20
Milan 20
Wilmington 20
Redmond 19
Seattle 19
Lappeenranta 18
Woodbridge 18
Cambridge 17
Helsinki 17
Da Nang 16
Biên Hòa 15
Dongguan 15
Quận Bình Thạnh 14
Johannesburg 13
Rome 13
Shenzhen 13
Ann Arbor 12
Ha Long 12
Lomé 12
Ninh Bình 12
Thái Nguyên 12
Bengaluru 11
Buffalo 11
Atlanta 10
Frankfurt am Main 10
Guangzhou 10
Munich 10
Redondo Beach 10
Điện Bàn 10
Can Tho 9
Hyderabad 9
Quận Một 9
Amsterdam 8
Chicago 8
Nanjing 8
Shanghai 8
Vũng Tàu 8
Amman 7
Bắc Giang 7
Bắc Ninh 7
Hải Dương 7
Mexico City 7
Brooklyn 6
Bến Tre 6
Fabriano 6
Madrid 6
Quận Phú Nhuận 6
Sofia 6
Turku 6
Vienna 6
Vinh 6
Warsaw 6
Bremen 5
Falkenstein 5
Jakarta 5
Nuremberg 5
Orem 5
Paris 5
Quảng Ngãi 5
Rio de Janeiro 5
San Francisco 5
Stockholm 5
Wuhan 5
Ankara 4
Berlin 4
Bettystown 4
Brescia 4
Cernusco sul Naviglio 4
Changsha 4
Chongqing 4
Curitiba 4
Florence 4
Huế 4
Lang Son 4
Totale 2.869
Salva come PNG Salva come JPEG
Nome #
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 714
Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma 238
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma 216
Hypoxia Decreases ROS level in human fibroblasts 215
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study 212
Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study 211
Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma 191
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma 190
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma 172
The inhibitor protein (IF1) of the F1F0-ATPase modulates human osteosarcoma cell bioenergetics 164
Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients 129
null 125
Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients 123
Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma 122
Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma 122
Interference of daratumumab and efficacy of plerixafor on haematopoietic stem cell collection in Multiple Myeloma 121
The role of the ATPase inhibitor factor 1 (IF(1)) in cancer cells adaptation to hypoxia and anoxia 119
Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients—A Systematic Review 119
Case Report: Uncommon co-occurrence of different renal histopathological entities in a patient with multiple myeloma and lymphoplasmacytic lymphoma 116
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial 112
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study 100
How I Treat High-risk Multiple Myeloma 98
null 96
T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS 95
Bispecific Antibodies and CAR T in Multiple Myeloma: Appropriate Selection of Patients and Sequencing 94
Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies? 89
MicroRNAs in Oncogenesis and Tumor Suppression 89
Ten-year experience on home care for patients with plasma cell disorders: bringing optimal therapy home 84
Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma 75
A multicenter observational retrospective study of second-line treatment with daratumumab–bortezomib–dexamethasone (DaraVd) in multiple myeloma patients refractory to lenalidomide 74
Correction: Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma 57
Totale 4.682
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.090
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.090
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022255 6 10 10 14 17 7 3 18 19 33 75 43
2022/2023330 42 46 6 52 14 31 11 16 67 10 25 10
2023/2024131 10 17 6 7 8 20 9 38 2 4 5 5
2024/2025620 26 27 52 60 57 18 41 15 25 68 75 156
2025/20262.916 299 646 195 211 195 161 223 100 459 177 138 112
2026/202772 72 0 0 0 0 0 0 0 0 0 0 0
Totale 4.682